10-Q: OSR Holdings Q1 2026: Revenue Declines, Gross Margins Improve

OSR Holdings reported a 36% decrease in net sales for Q1 2026, but saw gross profit margins improve to 33% due to a shift to a consignment model.

Summary

• OSR Holdings reported a net loss of $3,467,174 for the three months ended March 31, 2026, compared to a net loss of $11,392,814 for the same period in 2025.
• Net sales decreased by 36% to $484,057 in Q1 2026 from $761,271 in Q1 2025.
• Cost of sales decreased by 45%, leading to a 5% decrease in gross profit to $160,281.
• Gross profit margin improved from 22% in Q1 2025 to 33% in Q1 2026, attributed to a change in RMC's contractual arrangement to a consignment-based model.
• Selling, general, and administrative (SG&A) expenses increased by 24% to $3,827,465 in Q1 2026, primarily due to higher personnel and professional service costs.
• Operating loss widened by 26% to $3,667,184 in Q1 2026.
• Other income (expense) improved significantly due to the absence of large merger-related expenses recorded in Q1 2025.
• The company had cash and cash equivalents of $1,566,701 as of March 31, 2026.
• The company entered into a definitive Global Exclusive License Agreement for VXM01 with BCME, with potential milestone payments up to $815 million.
• The company issued a senior secured convertible promissory note for $1,055,555.55 to White Lion Capital, LLC.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to declining revenues, increasing operating losses, and ongoing material weaknesses in internal controls, despite some positive developments like improved gross margins and a significant licensing deal.

Positives

• Gross profit margin improved to 33% in Q1 2026 from 22% in Q1 2025, driven by a shift to a consignment-based model for RMC.
• The company secured a definitive Global Exclusive License Agreement for VXM01 with BCME, which includes potential milestone payments of up to approximately $815 million.
• Cash and cash equivalents stood at $1,566,701 as of March 31, 2026, providing some operational liquidity.
• The net loss for the quarter significantly decreased to $3,467,174 from $11,392,814 in the prior year period.

Negatives

• Net sales decreased by 36% to $484,057 in Q1 2026 compared to $761,271 in Q1 2025.
• Operating loss increased by 26% to $3,667,184 in Q1 2026 from $2,917,826 in Q1 2025.
• Selling, general, and administrative expenses increased by 24% to $3,827,465 in Q1 2026, indicating rising operational costs.
• The company has an accumulated deficit of $40,101,342 as of March 31, 2026.
• Material weaknesses in internal control over financial reporting have not been fully remediated.

Risks

• The company has incurred significant operating losses and negative cash flows from operating activities since its inception.
• There is an urgent need for additional capital, and the company's ability to continue as a going concern is dependent on its ability to secure further financing.
• The company has material weaknesses in internal control over financial reporting that have not been fully remediated, which could adversely affect its ability to report financial information accurately.
• The company is subject to risks associated with its reliance on equity lines of credit, which can lead to dilution and price impact on its securities.
• The company faces risks related to the development and commercialization of its product candidates, including VXM01, and the success of its licensing agreements.

Future Outlook

OSR Holdings expects to continue utilizing its equity line of credit with White Lion until the end of its commitment period on December 31, 2026, while aiming to minimize dilution. The company also plans to implement less dilutive financing facilities like an At-the-Market (ATM) offering. Research and development expenses are expected to be between $2.5 million to $3.0 million per quarter starting in the second half of 2026, potentially increasing to $5.0 million to $6.0 million per quarter in the future.

Management Comments

• The improvement in profitability was driven by a change in RMC's contractual arrangement with one of its major suppliers, transitioning from a traditional purchase-and-resale model to a consignment-based arrangement under which only commission revenue is recognized.
• Management expects this consignment-based model to enhance the stability of gross profit margins in future periods.
• The increase in SG&A expenses was primarily attributable to higher personnel-related costs and professional service fees.
• Woori IO accounted for approximately 1% of total SG&A expenses, and therefore the overall impact from its initial inclusion as a newly consolidated subsidiary was immaterial.
• The Company intends to use the net proceeds from any sales of Common Stock under the Common Stock Purchase Agreement for general corporate purposes, including working capital, research and development, and other operating expenses.
• The Company intends to exercise a higher level of prudence and control in the execution of the ELOC in order to minimize the dilution and price impact it may have on the market for the Company's equity securities.
• The Company plans to implement new equity financing facilities that are generally considered less dilutive and more controllable than ELOC arrangements, such as an At-the-Market (ATM) offering.

Industry Context

StockSavvy.ai notes that OSR Holdings operates in the healthcare sector, encompassing biotech and medical device distribution. The company's strategic focus on acquiring and developing innovative healthcare solutions, including oral immunotherapies and design-augmented biologics, aligns with broader industry trends of seeking transformative therapies. The VXM01 licensing agreement with BCME, a significant potential milestone payment, reflects common industry practices for advancing drug candidates through development and commercialization.

Comparison to Industry Standards

• The gross profit margin of 33% for Q1 2026, while an improvement, is generally lower than established medical device distributors, which often see margins in the 40-50% range. However, the shift to a consignment model can stabilize margins.
• The significant increase in SG&A expenses (24%) is a concern, especially when compared to companies with more mature operations. This suggests potential inefficiencies or high costs associated with being a publicly traded entity and integrating new acquisitions.
• The net loss of $3.47 million in Q1 2026, while reduced from the prior year, indicates continued unprofitability, which is common for early-stage biotech companies but requires careful monitoring for companies aiming for commercialization.
• The company's reliance on equity financing, including an ELOC, is a common strategy for early-stage companies but carries risks of dilution and market impact, which is a standard consideration in the venture capital and biotech funding landscape.

Management Changes

Legal Proceedings

• A civil action filed by Benjamin Securities, Inc. seeking $425,000.00 in brokerage fees and costs remains pending.
• Chardan Capital Markets, LLC filed a complaint asserting claims for breach of contract and related causes of action; parties are currently engaged in settlement discussions.

Related Party Transactions

• The Group has a loan agreement with BCM Europe AG for $860,000 as of March 31, 2026.
• The Group has a loan agreement with Bellevue Global Life Sciences Investors LLP for $1,208,000 as of March 31, 2026.
• Key management received salaries totaling $150,837 for the three months ended March 31, 2026.

Stakeholder Impact

• Shareholders may experience dilution due to the continued use of the equity line of credit and potential future equity issuances.
• Employees may be impacted by the company's ongoing operational losses and need for capital, although the appointment of a COO could signal a focus on operational efficiency.
• Creditors and lenders face increased risk given the company's accumulated deficit and reliance on external financing.

Next Steps

• Continue to utilize the ELOC with White Lion until December 31, 2026, while seeking less dilutive financing options.
• Implement new equity financing facilities, such as an ATM offering.
• Incur and report R&D expenses of approximately $2.5 million to $3.0 million per quarter starting in the second half of 2026.
• Continue remediation efforts to address material weaknesses in internal control over financial reporting.
• Pursue development and commercialization of VXM01 under the global exclusive license agreement with BCME.

Key Dates

Recommendation

The company shows signs of operational improvement with better gross margins and a significant licensing deal, but the continued revenue decline, widening operating loss, and unresolved internal control weaknesses present substantial risks. A 'hold' recommendation reflects the uncertainty and the need for further evidence of sustained operational improvement and successful capital raising before considering a more positive or negative stance.

Keywords

OSR Holdings, 10-Q, Quarterly Report, Healthcare, Biotech, Medical Devices, Financial Results, VXM01, Licensing Agreement, Capital Raise